title: [Oral enoximone therapy as a therapeutic bridging before heart transplantation].
abstract: A 58-year-old male patient with end-stage cardiomyopathy suffered from cardiac decompensation under parenteral catecholamine medication. Oral therapy with 450 mg Enoximone daily achieved recovery after 4 weeks, so that an orthotopic cardiac transplantation could be performed. The postoperative outcome was uneventful. Selective phosphodiesterase-inhibitors help to fill a therapeutic gap in the management of catecholamine-refractory heart failure.
authors: Klinik für Thorax-, Herz- und Gefässchirurgie, Fulda.
authors: H E
authors: HE
authors: Zeplin
authors: T
authors: T
authors: Stegmann
authors: J J
authors: JJ
authors: Fell
authors: H T
authors: HT
authors: Dressler
authors: H A
authors: HA
authors: Dieterich
mesh_terms: D000284:Administration, Oral; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D004452:Echocardiography; D017335:Enoximone; D016027:Heart Transplantation; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D011300:Preoperative Care; D012770:Shock, Cardiogenic / Q000188:drug therapy
chemical_list: D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone
vernacular_title: Orales Enoximon--Therapie als Uberbrückung vor Herztransplantation.